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Abstract 
 
Background: Fetal structural anomalies (FSA) detected by ultrasonography have a range of genetic 
aetiologies including chromosomal aneuploidy, copy number variations (CNVs) detectable by 
chromosomal microarrays (CMA) and pathogenic sequence variants in developmental genes. Investigations 
to detect aneuploidy and CNVs are routinely used for the investigation of FSA but information on the 
clinical utility of genome-wide next generation sequencing in the prenatal setting is limited.  
Methods: Whole exome sequencing (WES) was performed, after exclusion of aneuploidy and large CNVs, 
on a prospective cohort of 392 fetuses with FSA and in 772 parental samples (380 case-parental trios and 
12 case-parent dyads). Sequencing was interpreted based on a targeted developmental disorder virtual gene 
panel comprising 1536 genes. Genetic results relevant to the phenotype were validated and reported after 
the pregnancy was completed.    
Findings: After bioinformatic filtering and prioritisation, 201 genetic variants representing 155 potential 
diagnoses were selected as “potential pathogenic variants” and reviewed by a multidisciplinary clinical 
review panel (CRP). A diagnostic genetic abnormality was identified in 34/392 cases (8∙7%;95%CI:6∙1-
11∙9%) and a further 12(3∙1%) had a variant of uncertain significance (VUS) with potential clinical utility.  
Variant detection enabled syndromic and non-syndromic cases of fetal anomaly to be distinguished. 
Diagnostic variants were more common in fetuses with multisystem anomalies (more than one FSA) 
(16∙9%(13/77)), cardiac anomalies (18∙4%,(9/49)), skeletal anomalies (15∙4%,(6/39)) and hydrops fetalis 
(10∙5%,(2/19)) and less frequent in fetuses with isolated increased nuchal translucency (>4∙0 mm) in the 
first trimester (1∙1%, (1/88)).  
Interpretation: WES facilitates genetic diagnosis in FSAs enabling more accurate prediction of fetal 
prognosis and risk of recurrence in future pregnancies. However the overall detection rate in a prospectively 
ascertained, unselected cohort is lower than that suggested by previous smaller-scale studies of highly 
selected phenotypes.  
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Research in context  
 
Evidence before this study: 
Genome wide sequencing strategies such as whole exome (WES) or whole genome sequencing greatly 
increase the diagnostic yield over postnatal chromosomal microarray analysis (CMA) in children with 
developmental disorders. Previous, relatively small studies have suggested that the addition of WES to 
CMA for the investigation of fetal structural anomalies diagnosed by prenatal ultrasound could enable a 
genetic diagnosis to be made in the majority of cases with a FSA. However most such studies have been 
retrospective and include a small number (<30 cases) of highly selected subgroups of FSA; they provide 
limited information regarding the likely diagnostic yield in clinical practice of the application of WES for 
FSAs. 
Added value of this study 
In a prospectively ascertained cohort of FSA detected using prenatal ultrasound (in which aneuploidy and 
large copy number variants had been excluded) the overall diagnostic yield was 8∙7% after bioinformatic 
filtering of the WES and assessment by a multidisciplinary clinical review panel to reach consensus as to 
whether a WES finding was pathologic and causative. These data confirm that the addition of prenatal 
WES to CMA would increase the detection of genetic causes of FSA and provide important information 
on prognosis and future recurrence risks. The WES diagnostic yield varied with type of FSA suggesting 
that WES might be targeted to the phenotypic classes with highest clinical utility. The Prenatal 
Assessment of Genomes and Exomes study (PAGE) study also highlighted differences between the 
application of WES in the prenatal and postnatal period that will facilitate the translation of WES for FSA 
into clinical practice. 
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Introduction 
 
Approximately 3% of pregnancies will have a sonographically detected fetal structural anomaly (FSA) 
which may range from a single minor defect to severe multisystem anomalies incompatible with life.(1) 
Genetic investigations play an important part in the evaluation and clinical triage of FSAs. For many years 
prenatal  ‘conventional’ cytogenetic analysis was the first line investigation but more recently chromosomal 
microarray analysis (CMA) has been widely adopted to detect submicroscopic pathogenic copy number 
variations (CNVs).(2,3) Adding CMA testing to karyotyping increases the detection rate of chromosomal 
abnormalities by 3-5%.(2–4) FSAs may be associated with all types of genetic variation including aneuploidy, 
uniparental disomy (UPD), CNVs and intragenic mutations. There is increasing interest in the genome-
wide sequencing strategies to investigate prenatally detected congenital abnormalities. Though prenatal 
whole genome sequencing (WGS) has been described,(5) whole exome sequencing (WES) or targeted gene 
panels has received more interest because of the lower cost, limited amounts of fetal DNA available, 
requirement for rapid turnaround and greater sequencing depth. (6–13). Previously we performed WES in 29 
fetal-parental trios with an ultrasound detected FSA and identified a causative diagnosis in 10% of cases.(7) 
WES for the investigation of a range of FSA has been associated with a “diagnostic rate” of >50% but most 
previous studies have been small (<30) and/or confined to highly selected subgroups (see supplementary 
Table 1).(14,15) 
To define the potential utility of genome-wide sequencing strategies in prenatal diagnosis of FSA a large-
scale sequencing project, the Prenatal Assessment of Genomes and Exomes study (PAGE; 
http://www.pageuk.org) was initiated. In this paper we report on the experience to date of the clinical review 
panel (CRP) in considering the results of WES from 392 probands (and parental samples) presenting with 
a wide range of FSAs and highlight the issues encountered to date that have implications for the translation 
of prenatal WES into clinical practice.  
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Methods 
 
Subject recruitment and sample processing: Two groups (the Fetal Medicine Unit, Birmingham Women's 
& Children’s Foundation Trust/University of Birmingham and North East Thames Regional Genetics 
Laboratory, Great Ormond Street NHS Foundation Trust, London) coordinated patient recruitment through 
a network of 30 fetal medicine units across England and Scotland (Supplementary Figure 1). Following 
detection of a FSA at a routine ultrasound scan (USS) parents opting for invasive testing were offered the 
opportunity to participate in PAGE. All participants gave written informed consent and the study was 
approved by Research and Development offices at each of the participating institutions and by relevant 
Research Ethics Committees (NRES Committees:West Midlands-South Birmingham and London-
Harrow). Parental blood samples were collected for DNA extraction and fetal DNA was obtained from 
chorionic villi, amniotic fluid or fetal blood remaining after routine investigations (cases were excluded 
when these revealed aneuploidy/CNV explaining the phenotype). DNA was extracted at the two 
coordinating centres and shipped to the Wellcome Sanger Institute for WES. Participants were informed 
that the results of PAGE genetic analyses would not be available during the current pregnancy and only 
results relevant to the USS-detected FSA would be reported back to parents. To ensure that a range of 
phenotypes were included, prior to study it was agreed that the number of recruits with a specific phenotype 
would be capped at 20% of the total. 
Exome sequencing, variant detection and annotation: After WES, candidate pathogenic variants in a 
modified developmental disorder-associated gene list (see supplementary methods and supplementary 
Table 2)(16) were assessed and rare, protein altering variants where the inheritance pattern of the variant 
matches that of the gene were selected for clinical review. Sequencing data is available from the European 
Genome-phenome Archive (https://www.ebi.ac.uk/ega/). 
Data interpretation and variant classification: Candidate pathogenic variants were reviewed and classified 
by a clinical review panel (CRP) comprising at least six participants (including at least a clinical geneticist, 
a fetal medicine specialist, two clinical scientists and a bioinformatician) from the study team and, usually, 
a clinical geneticist and clinical laboratory scientist from the recruitment centre. Initially CRP meetings 
were face-to-face but subsequently distant participants joined by Webex/teleconferencing. All participants 
reviewed anonymised variant annotation data and clinical findings through the Sapientia (Congenica, UK) 
software. The CRP reached a consensus decision regarding variant classification (pathogenic/likely 
pathogenic/variant of uncertain significance/likely benign/benign) and relationship to prenatal sonographic 
phenotype. Causative pathogenic/ likely pathogenic variants were confirmed by Sanger sequencing in a 
NHS accredited laboratory. Research reports were issued to the local clinical geneticist/fetal medicine 
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specialist. Other types of variants were not validated or reported except in the case of a VUS that the CRP 
considered to have potential clinical utility. 
Statistical analysis: Variants were annotated with the probability of the relevant gene being loss of function 
intolerant (pLI).(17) pLI scores were compared using the Mann-Whitney U test. The diagnostic rate 
between different phenotypic classes was compared using Fisher's Exact test. All statistical analyses were 
conducted using R (version 3∙1∙3).  
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Results 
 
Ultrasound (USS) anomalies   
The 392 probands (164 female, 228 male) were categorised into 11 phenotypic classes according to the site 
of the USS-detected anomalies (see supplementary Table 3): abdominal(n=29), brain(n=38), cardiac(n=49), 
thoracic(n=12), facial(n=21), fetal hydrops(n=19), increased nuchal translucency(>4∙0mm)(n=88),  
renal(n=12), skeletal(n=39), spinal(n=8) and complex/multisystem anomalies(>2 FSAs detected) (n=77) 
(Supplementary Table 5). 
 
Variant assessments  
201 genetic variants, representing 155 potential diagnoses in 126 individuals were reviewed by the CRP 
(see Supplementary Table 4 and supplementary results). The mean number of potential diagnoses per 
proband considered by the CRP was 0∙40 (range 0-4). For complete trios (n=380), this value was 0∙37 
(range 0-4), while for dyads (n=12) this value was 1∙08 (range 0-4). 
 
The CRP assessed variants in 126 different developmental disorder genes with a median of one case per 
gene, however, 14 genes were assessed in multiple cases (KMT2D in 4 cases, FLNA in 3, and NRAS, CHD7, 
COL1A1, ZC4H2, ATP13A2, COL6A3, CHRNG, CDH23, HYDIN, BRCA1, RYR1 and COL18A1 in 2 each) 
(Figure 1A and 1B).   
 
Of the 155 potential diagnoses (comprising 187 SNVs and indels, 12 CNVs and 2 UPDs) in 126 probands 
(32∙1% of all cases analysed) considered, 34/392 probands were classed as harbouring likely pathogenic or 
pathogenic (LP/P) variant(s) relevant to the fetal anomaly (see Table 1), giving a diagnostic rate of 8∙7% 
(95% CI 6∙1 to 11∙9%). Twenty (59%) of the cases with a diagnostic variant had a de novo mutation (11 
truncating, 8 missense and 1 in-frame insertion), 13 cases had inherited the relevant mutation(s) (11 
autosomal recessively inherited disorders and two dominantly inherited disorders) and the final diagnosis 
had a chromosome 15 UPD. Factors associated with an increased likelihood of a diagnostic variant were 
protein truncating variants in monoallelic genes (diagnostic in 11/13 (84∙6%) cases compared to 26∙7% 
(8/30) for de novo missense variants in monoallelic genes, and de novo variants in a monoallelic disease 
gene (diagnostic in 20/45 cases (44∙4%)), compared to other potential diagnoses ((CNVs, inherited variants, 
UPDs) with 12∙7% diagnostic rate (14/110)). Genes harbouring diagnostic SNVs and indels had a higher 
median pLI than non-diagnostic variants (diagnostic=0∙91, non-diagnostic=0∙74) although this difference 
did not reach statistical significance (P=0∙1652).  
  
10 
 
Three of the 14 genes were considered by the CRP in multiple cases harboured diagnostic variants in two 
or more cases (KMT2D (n=3), COL1A1 (n=2) and CHRNG (n=2)) (see Figure 1B).  Cases with diagnostic 
KMT2D mutations (all de novo truncating) were present in multiple phenotypic classes (one multisystem, 
one cardiac and one hydrops).  
 
To our knowledge, this PAGE cohort includes the first instances of the prenatal identification of mutations 
in ANKRD11, ARCN1, CCDC103, COQ9, DNAH11, GATA4, MYCN, NR2F2, TAB2, TUBB and ZC4H2 
(Table 2). Further details of selected cases are provided in Case Reports #1 and #3 (see supplementary 
material).  
 
The diagnostic rate varied between the phenotypic groups (see figure 1C and supplementary Table 5). The 
highest diagnostic rates were in those with cardiac anomalies (18∙4% (9/49), p=0∙02 compared to all other 
phenotypes), multisystem fetal anomalies (16∙9% (13/77), p = 0∙01), skeletal anomalies (15∙4% (6/39)) and 
hydrops fetalis (10∙5%, (2/19)). Diagnostic rates in all other groups were <4% and the diagnostic rate in 
those with isolated increased nuchal translucency (>4∙0mm) was significantly lower than in all the other 
phenotypes combined (1/88, p= 0∙002).  
 
Consequences of a positive diagnosis were a low recurrence risk in 21 cases (20 with de novo mutations in 
monoallelic disease genes and one UPD) and high recurrence risk in 13 cases with inherited variants (11 
autosomal recessive and 2 dominant disorders). None of the diagnostic variants would currently, if detected 
in an ongoing pregnancy, have led to in utero fetal therapy. However, “in pregnancy” diagnosis could 
influence decisions about pregnancy outcome, e.g. in cardiac cases diagnostic variants were found in genes 
associated with postnatal extracardiac manifestations, including, learning disability (e.g. KMT2D, 
ANKDR11, SOS1, CCDC103). In pregnancy diagnosis might have enabled (in cases in which the parents 
choose to continue the pregnancy) better postnatal management (e.g. monitoring for neonatal 
hypoglycaemia in a Beckwith-Wiedemann syndrome fetus with exomphalos and a CDKN1C mutation) and 
it has been suggested that CoQ10 treatment might be helpful in COQ9-deficient children.(18) 
 
Clinically relevant non-diagnostic findings 
In addition to 34 WES-diagnosed cases, a further 12 cases had variants that were not considered diagnostic 
but merited further clinical and/or molecular investigations and were reported as “clinically-relevant-VUS” 
(see supplementary Table 6). These included a fetus with micrognathia, radial aplasia, ulnar and fibular 
hypoplasia, tibial and femoral shortening and an abnormal lumbar spine (probable hemivertebrae) on 
prenatal USS with compound heterozygous nonsense (c.2269C>T, p.Gln757Ter) and missense variants 
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(c.1580C>G, p.Thr527Arg) in RECQL4. Though the nonsense variant was considered pathogenic the 
missense substitution was classified as a VUS. Biallelic pathogenic variants in RECQL4 are associated with 
radial aplasia/hypoplasia syndromes and further follow up was considered to be indicated. In another case 
(PP0722) a de novo missense KMT2D variant was detected in a fetus with a 6∙7mm nuchal translucency  in 
the 1st trimester (see Text Box 1). In a further case an apparently pathogenic de novo nonsense variant in 
CHD7 was detected (PP1720) but the relevance to the prenatally detected brain ventriculomegaly was 
uncertain in the absence of any other features of CHARGE syndrome.  
 
Adding the 12 cases with potentially clinically relevant variants to the 34 diagnostic cases gave a total of 
46 (11∙7%, 95%CI 8∙7-15∙3%) in which WES provided a clinically relevant result.  
 
Ethical aspects of prenatal whole exome sequencing 
A detailed study of the ethical issues surrounding WES in prenatal diagnosis is in progress and has been 
reported separately.(19) Issues noted in the cases reported here included (a).identification of potentially 
pathogenic variants that might carry a recurrence risk but were apparently unrelated to the detected FSA 
and so, in accordance, with the ethical approval not reported, (b).identification of a VUS in a relevant 
candidate gene. Postnatally this might be handled by more detailed phenotyping and/or periodic review but 
in the prenatal setting phenotypic information is generally more limited and delaying a diagnostic decision 
is usually not an option. This is particularly difficult if the FSA might have a benign prognosis (e.g. talipes 
equinovarus anomaly); (c). detection of a heterozygous pathogenic variant in a relevant developmental gene 
associated with autosomal recessive disease, (d) detection of a pathogenic variant predicting late-onset adult 
disease (e.g. increased breast cancer risk in a mother found to be a carrier of a Fanconi anaemia gene variant) 
that is not relevant to the fetal abnormality.  
 
Pregnancy outcome data 
Pregnancy outcome was available in 316/392 cases (80∙6%). In 88 the parents opted for termination, 7 
ended in miscarriage, there were 13 stillbirths, 9 neonatal deaths, and 199 were live born babies. Of the 34 
cases with a WES diagnosis, post mortem or postnatal follow up was available in 31 cases (91∙2%) and was 
consistent with the molecular diagnosis. To our knowledge a postnatal genetic diagnosis hasn’t been made 
in any of the cases reviewed by the CRP and designated as having a variant without clinical relevance. 
However a diagnosis of Noonan syndrome was made in a child with a maternally inherited pathogenic RIT1 
variant (NM_006912∙5(RIT1):c.284G>C (p.Gly95Ala)). This variant was not considered by the CRP as it 
did not pass bioinformatic filtering because the mother was designated as normal phenotype.  The 
diagnostic yield for P/LP variants was significantly higher in cases with fetal demise (19/117) (miscarriage 
12 
 
(0/7), termination of pregnancy (15/88), stillbirth (2/13), neonatal death (2/9) than in those cases resulting 
in a live birth (12/199): 16∙2% versus 6∙0% (P=0∙005).  
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Discussion 
 
In this large prospectively collected series of 392 probands with FSA detected by prenatal USS in a fetal 
medicine centre we identified a relevant diagnostic genetic variant in a developmental disorder gene in 
8∙7% (34/392). In addition, in a further 12 cases a genetic variant considered to be of potential clinical 
utility was identified and reported and so overall 11∙7% (46/392) of cases had a diagnostic or potentially 
clinically relevant variant. Previously published WES studies of FSA cohorts have reported diagnostic rates 
>50% (14) but most studies comprise small numbers of highly selected cases and the designation of variants 
as diagnostic was less stringent. The largest previous study reported in full performed WES on 84 deceased 
fetuses with diagnostic results in 20%. (11) Our lower diagnostic yield reflects differences in ascertainment 
strategies as we prospectively recruited all suitable cases and then undertook WES without genetic review 
(after aneuploidy and large CNVs were excluded) whereas Yates et al (11) studied deceased fetuses after 
termination of pregnancy or spontaneous fetal death. Around half of our cohort were live born (and had a 
lower diagnostic yield than cases with fetal demise) and the diagnostic yield in our cases associated with 
fetal demise was close to that reported by Yates et al.(11) The results of genome-wide sequencing in 
unselected idiopathic FSA are especially relevant when considering the potential for translating WES into 
clinical practice. We note that in a meeting abstract Wapner et al reported a causal pathogenic variant in 
7∙5% of sequential cases of FSA (a further 5∙5% had a karyotype or CMA anomaly). (20) 
WES diagnostic yields in FSA are significantly less than that reported (up to 43%) in children with 
developmental disorders despite a similar sequencing and interpretation strategy.(16,21) This reflects 
differences in ascertainment as the postnatal cohort was selected after assessment by clinical genetics 
specialists (and therefore enriched for likely monogenic disorders), whereas the PAGE cohort includes 
manifestations such as isolated large nuchal translucency, isolated talipes and neural tube defects all of 
which are known to have a low association with a monogenic aetiology. Additionally, greater imprecision 
in prenatal versus postnatal phenotyping may also contribute (e.g. postnatally expert dysmorphology 
developmental assessment is more readily available and can facilitate variant interpretation and increase 
diagnostic yield).  
We found higher diagnostic yields with cardiac anomalies, complex/multisystem anomalies, skeletal 
anomalies, and, to a lesser extent, hydrops fetalis but detection rates were <4% with other types of 
anomalies. KMT2D likely pathogenic variants were the most frequent diagnostic finding and were 
associated with a variety of phenotypes including  multisystem anomalies (PP1843), isolated complex 
cardiac defect (PP1864) and fetal hydrops and cystic hygroma (PP1573). KMT2D mutations cause Kabuki 
syndrome which is characterised by developmental delay, epilepsy, cardiac, genitourinary and 
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musculoskeletal anomalies and distinctive facial features.(22–25) Although the presentation of Kabuki 
syndrome with fetal hydrops has been reported previously, the distinctive facial dysmorphology is less 
apparent in infancy than older children and diagnosis may be difficult in the early postnatal period.(25,26)  
To date prenatal WES studies have implicated a large number of developmental genes but 19 genes 
(including KMT2D) have been reported in multiple studies (Supplementary Table 1). To our knowledge, 
we report the first prenatally diagnosed cases of mutations in genes associated with isolated (NR2F2, TAB2) 
and syndromic congenital heart disease (primary ciliary dyskinesia/CCDC103; KBG 
syndrome/ANKRD11)) (see Table 2), so in cases of prenatally diagnosed cardiac defect, WES can provide 
important information on the non-cardiac prognosis. Other genes for which prenatally diagnosed cases had 
not apparently been reported included ARCN1, COQ9, MYCN, TUBB and ZC4H2 (see Text Box #1 and #3 
and Table 2).  
To maximise diagnostic yield we analysed variants in the 1421 developmental disorder genes included in 
the DDG2P panel (www.ebi.ac.uk/gene2phenotype) (downloaded 25/4/17), plus 116 genes identified as 
being associated with a prenatal presentation from the literature (Supplementary Table 2). This resulted in 
about a third of trios having at least one potential diagnostic finding. When implementing WES into clinical 
practice, there is a strong argument for curating the DDG2P list to remove genes not associated with FSA 
(e.g. causes of non-syndromic learning disability) and using smaller phenotype-specific virtual gene panels 
in order to reduce the number of VUS that are irrelevant to the FSA. Careful thought is also required as to 
which FSA cases should be investigated by WES/WGS. For non-specific FSAs which can be associated 
with a normal outcome (e.g. talipes equinovarous, resolving ventriculomegaly or an isolated small nuchal 
translucency) not only might the diagnostic rate of WES be small but finding a VUS could be problematic 
in the absence of such a non-specific phenotype.  
The PAGE study protocol does not, currently involve real time “in pregnancy” variant interpretation and 
reporting but decisions on variant classification/validation/reporting were based on information that would 
have been available for an ongoing pregnancy and provided insights into the challenges for translating 
prenatal WES into clinical practice. For rapid and efficient variant prioritisation fetal-parental trio analysis 
is clearly preferable to fetus-only WES as trios enables rapid identification of de novo variants in 
monoallelic developmental disorder genes and defines whether heterozygous pathogenic variants in 
biallelic genes are in cis or in trans. Optimal variant interpretation requires a multidisciplinary approach 
and detailed clinical information, including the prenatal USS and family history should be available to the 
CRP (the importance of family history was illustrated by the finding of a familial MYCN variant (Text Box 
3) and a case of familial Noonan syndrome that was not referred to the CRP). Performing WES in a large-
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scale/central sequencing facility (as in PAGE) provides consistency of methodology and bioinformatic 
pipelines but makes face-to-face CRP meetings more difficult. We found that a virtual CRP enabled all 
relevant specialists (including the clinical staff who will communicate the results to the parents) to discuss 
the cases and reach a consensus. Currently, PAGE results are only communicated to women and their 
partners after the pregnancy is complete but our experience has highlighted some of the ethical issues that 
would be encountered in clinical practice (see above).  Many potential ethical issues (e.g. incidental 
findings, non-paternity etc.) are not unique to prenatal WES/WGS and can be managed according to 
standard policies but it is essential that parents receive clear information regarding which findings might 
(and might not) be reported.(19) The identification and addressing of practical ethical issues within the PAGE 
project illustrates the value of embedded ethics research and also highlights the importance of ethics support 
and training for health professionals for the successful introduction of the PAGE study protocols into 
clinical practice. It also highlights the need for guidelines for clinical implementation as have been 
published recently by the International Society of Prenatal Diagnosis. (27) 
It is critical that the clinical and molecular data from prenatal WES is added to a confidential database and 
shared widely in an anonymous manner (e.g. in DECIPHER for PAGE variants) so that variant 
interpretations can be improved and the prenatal genotype-phenotype associations defined. Such databases 
should be international to facilitate rapid accumulation of data.  
In addition to informing the current pregnancy management, WES/WGS can provide insight into recurrence 
risks and enable future prenatal genetic testing or preimplantation diagnosis (40% of PAGE cases with a 
diagnostic finding were associated with a high recurrence risk). Though many WES diagnoses were caused 
by low recurrence risk de novo mutations, such cases can be associated with a small increased recurrence 
risk from gonadal mosaicism and non-invasive prenatal diagnosis using analysis of circulating cell free 
fetal DNA in maternal plasma can be offered at an early stage of future pregnancies. (28) 
In conclusion, we report the largest study to date of WES for unselected FSA. Though the diagnostic yield 
is lower than that suggested by smaller, mostly retrospective, studies on selected groups, adding WES to 
CMA substantially increases the number of USS-detected FSA cases in which a genetic diagnosis can be 
made and improves the prognostic information that can be provided. This can have important implications 
for prognosis and recurrence risks. It seems inevitable that WES/WGS will be applied increasingly for 
investigating FSAs but large scale studies with careful curation of clinical and genomic data will greatly 
facilitate the challenges of incorporating WES/WGS into prenatal diagnostics.  
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Tables 
 
Table 1: Details of Diagnostic Variants classified by the PAGE Clinical Review Panel (see text for details) 
(hom=homozygous) 
 
PP_ID Phenotype Gene VEP Inheritance Zygosity 
PP0602 
Large 
NT>4.0 chr15 UPD chr15 UPD UPD NA 
PP0258 Abdominal MYCN missense 
inherited from 
affected parent Heterozygous 
PP1753 Multisystem CDKN1C frameshift_variant inherited Heterozygous 
PP0555 Multisystem EVC2 
frameshift_variant 
(hom) inherited Homozygous 
PP0318 Skeletal CHRNG 
frameshift_variant 
(hom) inherited Homozygous 
PP0342 Multisystem CHRNG frameshift_variant x 2 inherited Heterozygous 
PP0390 Cardiac CCDC103 missense_variant (hom) inherited Homozygous 
PP1627 Multisystem PIEZO1 missense_variant x 3 inherited Heterozygous 
PP1780 Multisystem TCTN2 splice_acceptor inherited Homozygous 
PP0659 Multisystem RAPSN splice_donor_variant inherited Homozygous 
PP0513 Cardiac DNAH11 stop gained inherited Homozygous 
PP1795 Multisystem COQ9 stop_gained (hom) inherited Homozygous 
PP2000 Multisystem RYR1 
stop_gained + 
frameshift_variant inherited Heterozygous 
PP0087 Skeletal DYNC2H1 stop_gained x 2 inherited Heterozygous 
PP1711 Facial SF3B4 frameshift de novo Heterozygous 
PP1750 Cardiac ANKRD11 frameshift_variant de novo Heterozygous 
PP0333 Cardiac GATA4 frameshift_variant de novo Heterozygous 
PP2033 Cardiac CHD7 frameshift_variant de novo Heterozygous 
PP1726 Cardiac TAB2 frameshift_variant de novo Heterozygous 
PP1573 Hydrops KMT2D frameshift_variant de novo Heterozygous 
PP0204 Skeletal ZC4H2 frameshift_variant de novo Heterozygous 
PP2009 Skeletal ARCN1 frameshift_variant de novo Heterozygous 
PP1462 Multisystem BRAF missense de novo Heterozygous 
PP1579 Brain TUBB missense_variant de novo Heterozygous 
PP0184 Cardiac NR2F2 missense_variant de novo Heterozygous 
PP0174 Multisystem NRAS missense_variant de novo Heterozygous 
PP1408 Multisystem SOX9 missense_variant de novo Heterozygous 
PP2015 Multisystem FLNB missense_variant de novo Heterozygous 
PP0792 Skeletal COL1A1 missense_variant de novo Heterozygous 
PP1934 Skeletal COL1A1 missense_variant de novo Heterozygous 
PP1892 Cardiac SOS1 protein_altering_variant de novo Heterozygous 
PP1864 Cardiac KMT2D splice_donor_variant de novo Heterozygous 
PP2039 Hydrops NIPBL stop_gained de novo Heterozygous 
PP1843 Multisystem KMT2D stop_gained de novo Heterozygous 
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Table 2: PAGE cases with diagnostic variants in genes without previous prenatal phenotype descriptions 
AVSD= atrioventricular septal defect; ASD= atrial septal defect 
 
 
Gene Postnatal phenotype Reference [number of 
postnatal cases in cited 
references] 
Prenatal USS PAGE 
findings (PAGE ID) 
ANKRD11  KBG syndrome, Coffin-Siris-like 
syndrome: intellectual disability, 
macrodontia, facial dysmorphisms, 
skeletal anomalies, short stature, 
hearing loss, recurrent middle palatal 
abnormalities 
 [89](29–31)  Atrioventricular canal 
defect (PP1750) 
ARCN1  Severe micrognathia, microcephaly, 
short stature with rhizomelic 
shortening, joint laxity, and mild 
developmental delay and, in some 
cases (each one case):  cardiac defect, 
cleft palate  
 [n=4](32) Absent/Hypoplastic 
radius, ulnar hyoplasia, 
fubular hypoplasia, short 
tibia, femur and humerus 
(PP2009) 
CCDC103 Primary ciliary dyskinesia (upper and 
lower airway infections, sinusitis,  
bronchiectasis, dextrocardia/ situs 
inversus, AVSD, immotile sperm).  
 [14](33–36) Complex univentricular 
heart, double outlet right 
ventricle (DORV), 
transposition great arteries 
(TGA), pulmonary 
stensosis, likely right atrial 
isomerism (PP0390) 
COQ9 Neonatal encephalopathy with  lactic 
acidosis, seizures, global 
developmental delay, hypertrophic 
cardiomyopathy, renal tubular 
dysfunction 
[n=2] (18,37) dilated loops of bowel, 
cardiomegaly, pericardial 
effusion, fetal growth 
restriction, anhydramnios 
(PP1795) 
MYCN Feingold syndrome (oesophogeal and 
duodenal atresias, microcephaly, 
learning disability, digital anomalies: 
brachymesophalang/ syndactyly); 
cardiac defects, renal anomalies,  
[77](38) See Text Box 3 (PP1579) 
NR2F2 AVSD, ASD, hypoplastic left heart 
syndrome, coarctation of the aorta, 
tetralogy of Fallot; congenital 
diaphragmatic hernia 
 [11] (39,40) Abnormal 4 chamber view 
of heart (PP0184) 
TAB2 Frontometaphyseal dysplasia; 
hypertelorism, wide nasal bridge, 
micrognathia, hearing loss, congenital 
heart defects (variable), scoliosis, 
upper limb contractures 
 [15](41–44) Increased NT (8.0 mm) 
PP1726 
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TUBB  Microcephaly, structural brain 
anomalies (dysmorphic basal ganglia, 
abnormalities of 
the corpus callosum, and brainstem 
hypoplasia), learning disability, 
circumferential skin creases, cleft 
palate, short stature 
 [6](45,46) See Text Box 1 
(PP1579) 
ZC4H2 Arthrogryposis multiplex congenita, 
kyphosis/scoliosis, severe learning 
disability 
 [5](47) Fixed extended knees, 
rocker bottom feet, flat 
forehead 
(PP204) 
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Figure legends 
 
Figure 1. A. Number of potential diagnoses per case reviewed by clinical review panel, B. Number of 
potential diagnoses reviewed by the clinical review panel by gene for all genes harbouring a diagnostic 
variant and for all genes considered for more than one proband (regardless of diagnostic status), C. 
Proportion of cases for each phenotypic class for all cases, for cases with a diagnostic variant(s) and for 
cases considered by the clinical review panel with non-diagnostic variants. 
 
Figure 2: Pregnancy outcomes (live birth/miscarriage/termination of pregnancy/stillbirth or neonatal 
death/lost to follow up (LTFU) or unknown) for different phenotypic classes of fetal anomaly.  Total 
number of cases for each group were abdominal (n=29), brain(n=38), cardiac (n= 49), thoracic (n=12), 
facial (n=21), fetal hydrops (n=19), increased nuchal translucency (>4.0mm) (n=88),  renal (n=12), skeletal 
(n=39), spinal (n=8) and complex/multisystem anomalies (n=77) 
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Figure 2: 
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